These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21130255)

  • 41. [Hormonal treatment in cancer of the prostate].
    Boccon-Gibod L
    Rev Prat; 1987 Feb; 37(7):386-90. PubMed ID: 3823774
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of an evidence-based education package for men with prostate cancer on hormonal manipulation therapy.
    Templeton H; Coates V
    Patient Educ Couns; 2004 Oct; 55(1):55-61. PubMed ID: 15476990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Secondary hormonal therapy.
    Smith DC
    Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
    Morabito N; Gaudio A; Lasco A; Catalano A; Atteritano M; Trifiletti A; Anastasi G; Melloni D; Frisina N
    J Bone Miner Res; 2004 Nov; 19(11):1766-70. PubMed ID: 15476575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
    Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
    Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Researchers probe consequences of androgen deprivation for prostate cancer.
    Friedrich MJ
    JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787
    [No Abstract]   [Full Text] [Related]  

  • 48. Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
    Mitsuzuka K; Arai Y
    Int J Urol; 2018 Jan; 25(1):45-53. PubMed ID: 29052905
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Innovations in the systemic therapy of prostate cancer.
    Shepard DR; Raghavan D
    Nat Rev Clin Oncol; 2010 Jan; 7(1):13-21. PubMed ID: 19997075
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What do Canadian uro-oncologists believe patients should know about androgen deprivation therapy?
    Tran S; Walker LM; Wassersug RJ; Matthew AG; McLeod DL; Robinson JW
    J Oncol Pharm Pract; 2014 Jun; 20(3):199-209. PubMed ID: 24122850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular risks of androgen deprivation therapy.
    Ribeiro AF; Camara C; Segre CA; Srougi M; Serrano CV
    Arq Bras Cardiol; 2010 Sep; 95(3):412-5. PubMed ID: 20944900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer.
    Gilbert SE; Tew GA; Fairhurst C; Bourke L; Saxton JM; Winter EM; Rosario DJ
    Br J Cancer; 2016 Feb; 114(4):401-8. PubMed ID: 26766737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse effects of androgen deprivation therapy in patients with prostate cancer: Focus on muscle and bone health.
    Bargiota A; Oeconomou A; Zachos I; Samarinas M; L Pisters L; Tzortzis V
    J BUON; 2020; 25(3):1286-1294. PubMed ID: 32862568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Information Concerning Endocrine Therapy and Adherence of Patients with Breast and Prostate Cancer.
    Linke B; Liebl P; Marten D; Stoll C; Jung B; Wuensch P; Huebner J
    Clin Oncol (R Coll Radiol); 2015 Aug; 27(8):482-3. PubMed ID: 25869258
    [No Abstract]   [Full Text] [Related]  

  • 55. Complementary and alternative therapies for advanced prostate cancer.
    Smith MR
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):559-71. PubMed ID: 11525297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Re: does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
    Griebling TL
    J Urol; 2014 Jun; 191(6):1784-5. PubMed ID: 25280283
    [No Abstract]   [Full Text] [Related]  

  • 57. Osteoporosis in men with prostate cancer: now for the fracture data.
    Smith MR
    J Clin Oncol; 2008 Sep; 26(27):4371-2. PubMed ID: 18802147
    [No Abstract]   [Full Text] [Related]  

  • 58. [Observational study CAPITAL and prescription of hormonotherapy by French urologists in daily practice].
    de La Taille A; Drouin SJ; Rouprêt M; Perrin P; Zerbib M
    Prog Urol; 2009 Apr; 19 Suppl 1():S20-5. PubMed ID: 19465333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current topics and perspectives in the treatment of endocrine-related cancers.
    Iwase H
    Int J Clin Oncol; 2008 Oct; 13(5):377-9. PubMed ID: 18946746
    [No Abstract]   [Full Text] [Related]  

  • 60. Special issue on steroids and cancer. Preface.
    Geisler J; Sasano H
    J Steroid Biochem Mol Biol; 2012 Sep; 131(3-5):67. PubMed ID: 22732368
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.